Melioidosis represents a grave infectious threat. Leveraging our profound proficiency in melioidosis diagnostic research, we stand ready to deliver customized solutions and extensive assistance to ease your transition from melioidosis diagnostic research to commercialization.
Overview of Melioidosis
Melioidosis, a potentially fatal infectious disease caused by the bacterium Burkholderia pseudomallei, poses significant challenges in diagnosis. This illness, prevalent in regions such as Southeast Asia and Northern Australia, can manifest in various forms, affecting multiple organ systems and presenting diverse symptoms. Accurately and promptly diagnosing melioidosis is crucial to guarantee timely intervention.
Fig. 1 Schematic representation of host-pathogen interactions in melioidosis. (Wiersinga, et al., 2018)
Diagnostic Biomarkers for Melioidosis
Diagnostic biomarkers for melioidosis serve as measurable indicators of the presence of disease or specific disease-related processes in the body. These biomarkers may encompass genes, proteins, or other substances detectable in diverse bodily fluids or tissues. Identifying specific biomarkers associated with melioidosis could improve the efficiency of diagnostic tests and help differentiate this infection from other similar diseases.
Microbial Antigens
Specific microbial antigens of Burkholderia pseudomallei, such as lipopolysaccharide (LPS) and capsular polysaccharide, can be used to confirm the presence of the bacterium. Targeting unique antigens associated with the pathogen can help develop highly specific diagnostic tests for melioidosis.
Bacterial DNA
Bacterial genetic material provides valuable insights into the molecular characteristics of melioidosis. Molecular techniques such as polymerase chain reaction (PCR) and gene expression analysis can detect Burkholderia pseudomallei DNA in samples, allowing for rapid and accurate diagnosis of infection.
IVD Development for Melioidosis
In vitro diagnostic (IVD) kits are instrumental in the diagnosis of melioidosis. The significance of IVD kits in diagnosing melioidosis stems from their capacity to swiftly, precisely, and dependably detect the pathogen, thereby expediting timely and suitable medical interventions. Various types of IVD kits can be developed to assist in the diagnosis of melioidosis.
Melioidosis antigen detection kits commonly employ immunoassays to identify Burkholderia pseudomallei specific antigens in samples. These kits often utilize techniques such as ELISA and lateral flow immunoassays. By swiftly delivering results, antigen detection kits enable prompt diagnosis and commencement of therapeutics.
DNA detection kits typically utilize polymerase chain reaction (PCR) or other molecular techniques to amplify and detect specific gene sequences unique to Burkholderia pseudomallei. PCR-based tests are highly sensitive and specific, and can detect even small amounts of the pathogen's genetic material in a sample.
Our Services
Our company offers a wide range of IVD solutions specifically designed to meet the complex requirements of diagnosing melioidosis. We specialize in the development of IVD reagents/kits for antigen, DNA, and microbial detection, enabling precise diagnosis of this infectious disease. Leveraging cutting-edge diagnostic devices, our primary objective is to streamline and automate diagnostic processes, ultimately enhancing operational efficiency.
IVD Product Development Services
In response to the demand for swift diagnosis of melioidosis in resource-constrained environments, we provide point-of-care testing (POCT) development services aimed at expediting early detection and timely management of this intricate infectious disease. Our expertise in companion diagnostic development assists in devising optimal personalized therapeutic strategies for individuals grappling with melioidosis.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Wiersinga, W. Joost, et al. "Melioidosis." Nature reviews Disease primers 4.1 (2018): 1-22.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
